Zio XT ECG Monitoring System vs Eko Low Ejection Fraction Tool (ELEFT)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS

AI Verdict

Zio XT focuses on continuous, long-term ECG monitoring for arrhythmia detection and diagnosis using a wearable biosensor. In contrast, Eko Low Ejection Fraction Tool provides rapid, point-of-care screening for low ejection fraction, an indicator of heart failure, by integrating with digital stethoscopes during routine exams. While both are cardiology AI tools, they address different diagnostic needs and clinical workflows.

Choose Zio XT ECG Monitoring System if…

Choose the Zio XT ECG Monitoring System if you require continuous, long-term cardiac rhythm monitoring for up to 14 days to detect and diagnose intermittent arrhythmias that may not be evident during a brief clinical encounter. This system is ideal for patients needing comprehensive assessment of their heart's electrical activity over an extended period, offering high patient compliance with its comfortable, wearable design.

View Zio XT ECG Monitoring System →

Choose Eko Low Ejection Fraction Tool (ELEFT) if…

Choose the Eko Low Ejection Fraction Tool (ELEFT) if you need a rapid, non-invasive screening tool to aid in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical examinations. This AI-powered solution integrates seamlessly with Eko digital stethoscopes, providing quick insights within approximately 15 seconds to help identify at-risk patients in a primary care or general cardiology setting.

View Eko Low Ejection Fraction Tool (ELEFT) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio XT ECG Monitoring System Eko Low Ejection Fraction Tool (ELEFT)
Pricing Contact for pricing Unknown
Deployment Cloud-based (AWS EC2 platform), no on-premise hardware required. Unknown
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Tool A (Zio XT) offers superior patient usability for extended monitoring with its wearable, wire-free, and water-resistant design, leading to high patient compliance (up to 99%). While Tool B (ELEFT) provides quick results for clinicians, Tool A addresses more complex usability challenges for long-term patient engagement and data collection.

Clinical Value

Zio XT ECG Monitoring System

Tool A (Zio XT) provides comprehensive, continuous cardiac monitoring for up to 14 days, significantly increasing the diagnostic yield for intermittent arrhythmias. While Tool B (ELEFT) offers valuable early detection of low ejection fraction, Tool A's extended monitoring capability covers a broader range of cardiac diagnostic needs.

Pricing & Value

Zio XT ECG Monitoring System

Tool A (Zio XT) provides specific pricing examples for the UK (u00a3310 per patient) and US Medicare rates (approximately $229-$260.35), offering greater transparency. Tool B (ELEFT) only states 'contact for pricing' and that it's part of an enterprise platform, making it harder to assess its value proposition without direct inquiry.

Enterprise Readiness

Eko Low Ejection Fraction Tool (ELEFT)

Both tools are cloud-based, FDA-cleared, HIPAA compliant, and offer BAAs, indicating strong foundational enterprise readiness. However, Tool B (ELEFT) explicitly states it is part of Eko's SENSORAu2122 platform, an 'enterprise solution,' suggesting a more deliberate design and packaging for large-scale organizational deployments.

Innovation

Zio XT ECG Monitoring System

Tool A (Zio XT) demonstrates significant innovation in patient-friendly, long-duration ambulatory cardiac monitoring with its wire-free, water-resistant biosensor and high patient compliance. While Tool B (ELEFT) innovates by bringing AI-powered heart failure screening to the point of care, Tool A's advancements in continuous, comfortable, and highly compliant diagnostics for extended periods represent a broader innovation in wearable medical technology.

Support & Docs

Tie

Neither the provided structured facts nor general web searches reveal a significant differentiator in the quality or extent of support and documentation offered by either company. Both iRhythm Technologies and Eko Health, as established medical device companies, appear to provide standard support resources, FAQs, and contact information for healthcare professionals and patients.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio XT ECG Monitoring System Eko Low Ejection Fraction Tool (ELEFT)
Tool Name Zio XT ECG Monitoring System Eko Low Ejection Fraction Tool (ELEFT)
Company iRhythm Technologies Eko Health
Primary Function Wearable, single-lead ECG biosensor for up to 14 days of continuous cardiac monitoring, utilizing FDA-cleared AI and expert review for accurate arrhythmia detection and diagnosis. FDA-cleared AI algorithm that integrates with Eko digital stethoscopes to aid clinicians in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical exams.
Key Technology/Sensor Wearable single-lead ECG biosensor (Zio biosensor) AI algorithm integrated with FDA-cleared Eko digital stethoscopes
Monitoring Duration/Time to Result Continuous ambulatory cardiac monitoring for up to 14 days Provides results in approximately 15 seconds

Videos

Demos, reviews, and walkthroughs featuring Zio XT ECG Monitoring System and Eko Low Ejection Fraction Tool (ELEFT).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Zio XT ECG Monitoring System is designed for continuous cardiac monitoring to detect and diagnose arrhythmias over a period of up to 14 days. In contrast, the Eko Low Ejection Fraction Tool (ELEFT) aids in the early detection of low ejection fraction, a key indicator of heart failure, during routine physical examinations.
Zio XT utilizes a wearable, single-lead ECG biosensor that continuously records cardiac activity for up to 14 days, with data analyzed by an FDA-cleared AI algorithm and expert review. ELEFT integrates an FDA-cleared AI algorithm with Eko digital stethoscopes to analyze ECG and heart sound recordings, providing results in approximately 15 seconds during a physical exam.
Patients using Zio XT wear a water-resistant biosensor for up to 14 days, which has no external leads and includes a patient-activated button for symptomatic event logging. ELEFT is a non-invasive screening tool used by clinicians during a routine physical exam, integrating with a digital stethoscope.
Both Zio XT and ELEFT are relevant for Cardiology and Internal Medicine. Additionally, Zio XT is also applicable in Emergency Medicine, while ELEFT is also suited for Family Medicine.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.